3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Papillomavirus Infections
1
Neoplasms
1
Neoplasm Metastasis
1
Mycosis Fungoides
1
Leukoplakia
1
Leukokeratosis, Hereditary Mucosal
1
Glioma
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Interventions
aldesleukin
2
Adoptive Transfer
2
trastuzumab deruxtecan
1
talazoparib
1
liposomal doxorubicin
1
fludarabine
1
dostarlimab
1
belzutifan
1
apixaban
1
Vaccines, Synthetic
1
Therapeutic Touch
1
Surveys and Questionnaires
1
Surgical Procedures, Operative
1
Specimen Handling
1
Rivaroxaban
1
Radiotherapy
1
Radiation
1
Papillomavirus Vaccines
1
Paclitaxel
1
Observation
1
Nivolumab
1
Magnetic Resonance Spectroscopy
1
Imiquimod
1
Hysterectomy
1
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
1
Heparin, Low-Molecular-Weight
1
Gemcitabine
1
Fluorodeoxyglucose F18
1
FAPI-46
1
Doxorubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Vaginal Neoplasms
×
Imiquimod
×
Clear all
NCT06686043
2024-11-13
HPV-VIM
Baylor College of Medicine
Phase 2
Recruiting
85 enrolled